Merck to buy Terns Pharmaceuticals for $6.7 billion to boost cancer pipeline
Pharma large Merck is shopping for US biotech agency Terns Pharmaceuticals for $6.7 billion, the corporate mentioned Wednesday. This is the third multibillion-dollar acquisition for Merck over the previous yr as the corporate seems to be to bulk up its portfolio forward of its best-selling cancer drug Keytruda dropping patent safety in 2028. Merck will…
